Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;4(3):209-29.
doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24.

Triple-negative breast cancer: present challenges and new perspectives

Franca Podo  1 , Lutgarde M C Buydens, Hadassa Degani, Riet Hilhorst, Edda Klipp, Ingrid S Gribbestad, Sabine Van Huffel, Hanneke W M van Laarhoven, Jan Luts, Daniel Monleon, Geert J Postma, Nicole Schneiderhan-Marra, Filippo Santoro, Hans Wouters, Hege G Russnes, Therese Sørlie, Elda Tagliabue, Anne-Lise Børresen-Dale; FEMME Consortium
Affiliations
Review

Triple-negative breast cancer: present challenges and new perspectives

Franca Podo et al. Mol Oncol. 2010 Jun.

Abstract

Triple-negative breast cancers (TNBC), characterized by absence of estrogen receptor (ER), progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), are typically associated with poor prognosis, due to aggressive tumor phenotype(s), only partial response to chemotherapy and present lack of clinically established targeted therapies. Advances in the design of individualized strategies for treatment of TNBC patients require further elucidation, by combined 'omics' approaches, of the molecular mechanisms underlying TNBC phenotypic heterogeneity, and the still poorly understood association of TNBC with BRCA1 mutations. An overview is here presented on TNBC profiling in terms of expression signatures, within the functional genomic breast tumor classification, and ongoing efforts toward identification of new therapy targets and bioimaging markers. Due to the complexity of aberrant molecular patterns involved in expression, pathological progression and biological/clinical heterogeneity, the search for novel TNBC biomarkers and therapy targets requires collection of multi-dimensional data sets, use of robust multivariate data analysis techniques and development of innovative systems biology approaches.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lack of correlation between tumor size and nodal status among (A) triple‐negative breast cancers (TNBC) with tumor size smaller than 50 mm (χ2 test for trend: P = 0.47 for TNBC; P < 0.0001 for other breast cancer subtypes) and (B) BRCA1‐associated breast cancers (χ2 test for trend: P = 0.183 for BRCA1‐associated tumors; P < 0.0001 for BRCA2‐associated breast tumors and for breast tumors in non‐carriers). N+ positive nodal status (at least one positive lymph node). Graphs adapted from Dent et al. (2007) and (Foulkes et al. 2003a).
Figure 2
Figure 2
Integration of predictive expression signatures and altered cell signaling patterns in the search for pathway‐driven tumor therapeutics and bioimaging.
Figure 3
Figure 3
The flow, analysis and integration of multi‐dimensional molecular, biological and clinical data from different biomedical sources leading to a new classification system, diagnostic tools and predictive models in breast cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acharya, C.R. , Hsu, D.S. , Anders, C.K. , Anguiano, A. , Salter, K.H. , Walters, K.S. , Redman, R.C. , Tuchman, S.A. , Moylan, C.A. , Mukherjee, S. , Barry, W.T. , Dressman, H.K. , Ginsburg, G.S. , Marcom, K.P. , Garman, K.S. , Lyman, G.H. , Nevins, J.R. , Potti, A. , 2008. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 299, 1574–1587. - PubMed
    1. Aebersold, R. , Auffray, C. , Baney, E. , Barillot, E. , Brazma, A. , Brett, C. , Brunak, S. , Butte, A. , Califano, A. , Celis, J. , Cufer, T. , Ferrell, J. , Galas, D. , Gallahan, D. , Gatenby, R. , Goldbeter, A. , Hace, N. , Henney, A. , Hood, L. , Iyengar, R. , Jackson, V. , Kallioniemi, O. , Klingmuller, U. , Kolar, P. , Kolch, W. , Kyriakopoulou, C. , Laplace, F. , Lehrach, H. , Marcus, F. , Matrisian, L. , Nolan, G. , Pelkmans, L. , Potti, A. , Sander, C. , Seljak, M. , Singer, D. , Sorger, P. , Stunnenberg, H. , Superti-Furga, G. , Uhlen, M. , Vidal, M. , Weinstein, J. , Wigle, D. , Williams, M. , Wolkenhauer, O. , Zhivotovsky, B. , Zinovyev, A. , Zupan, B. , 2009. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol. Oncol. 3, 9–17. - PMC - PubMed
    1. Agrawal, A. , Gutteridge, E. , Gee, J.M. , Nicholson, R.I. , Robertson, J.F. , 2005. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer. 12, (Suppl. 1) S135–S144. - PubMed
    1. Alfieri, R. , Barberis, M. , Chiaradonna, F. , Gaglio, D. , Milanesi, L. , Vanoni, M. , Klipp, E. , Alberghina, L. , 2009. Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation. BMC Bioinformatics. 10, (Suppl. 12) S16 - PMC - PubMed
    1. Aulmann, S. , Adler, N. , Rom, J. , Helmchen, B. , Schirmacher, P. , Sinn, H.P. , 2006. c-myc amplifications in primary breast carcinomas and their local recurrences. J. Clin. Pathol. 59, 424–428. - PMC - PubMed

Publication types

MeSH terms